Skip to main content
. 2022 Sep 17;17(5):517–527. doi: 10.1007/s11523-022-00906-w

Fig. 2.

Fig. 2

Overall survival (OS) a since diagnosis, b since the start of first-line therapy, and c since the start of second-line therapy. CI confidence interval, FGFR fibroblast growth factor receptor, FGFR2 fibroblast growth factor receptor 2, iCCA intrahepatic cholangiocarcinoma, NE not estimable